Targeted therapy—anastrozole prevents breast cancer

The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women. While this is a major advance in prevention research, its impact on clinical practice will ultimately depend upon subject perception of risk, adverse effects and benefits...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Clinical oncology Vol. 11; no. 3; pp. 127 - 128
Main Author Brown, Powel
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2014
Nature Publishing Group
Subjects
692/699/67/1059/602
692/699/67/1347
692/699/67/2195
Breast cancer
Cancer
Care and treatment
Health aspects
Medicine
Medicine & Public Health
news-and-views
Oncology
Oncology, Experimental
Postmenopausal women
Prevention
Online AccessGet full text

Cover

More Information
Summary:The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women. While this is a major advance in prevention research, its impact on clinical practice will ultimately depend upon subject perception of risk, adverse effects and benefits of anastrozole versus other available cancer preventive therapies.
ISSN:1759-4774
1759-4782
DOI:10.1038/nrclinonc.2014.17